s6y Ocera Therapeutics, Inc. 10-Q

Ocera Therapeutics, Inc. 10-Q, filed Aug 13, 2014: IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2014
Fair Value Disclosures [Abstract]  
Assets and liabilities measured at fair value on a recurring basis
Assets measured at fair value on a recurring basis as of June 30, 2014 are as follows (in thousands):
 
Balance as of
June 30,
2014
 
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
9,427

 
$
9,427

 
$
—

 
$
—

Commercial paper
7,499

 
—

 
7,499

 
—

Corporate debt securities
19,612

 
—

 
19,612

 
—

Total assets
$
36,538

 
$
9,427

 
$
27,111

 
$
—

Assets measured at fair value on a recurring basis as of December 31, 2013 are as follows (in thousands):
 
Balance as of
December 31,
2013
 
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
5,774

 
$
5,774

 
$
—

 
$
—

Commercial paper
15,246

 
—

 
15,246

 
—

Corporate debt securities
20,884

 
—

 
20,884

 
—

Total assets
$
41,904

 
$
5,774

 
$
36,130

 
$
—